vs
Medpace Holdings, Inc.（MEDP）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $708.5M、Medpace Holdings, Inc.の約1.1倍）。Medpace Holdings, Inc.の純利益率が高く（19.1% vs 12.7%、差は6.3%）。Medpace Holdings, Inc.の前年同期比売上増加率が高い（32.0% vs 5.9%）。Medpace Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$188.1M vs $161.8M）。過去8四半期でMedpace Holdings, Inc.の売上複合成長率が高い（17.7% vs 9.0%）
Medpace Holdings, Inc.は米国オハイオ州シンシナティに本社を置くグローバルな臨床研究機関（CRO）で、従業員数は約6,000人です。フルサービス体制を採用し、グローバル中央検査室、画像コアラボ、生物分析検査室サービスを提供するほか、本社敷地内に第I相臨床試験部門を設けています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
MEDP vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $708.5M | $772.1M |
| 純利益 | $135.1M | $98.4M |
| 粗利率 | — | — |
| 営業利益率 | 21.6% | 14.5% |
| 純利益率 | 19.1% | 12.7% |
| 売上前年比 | 32.0% | 5.9% |
| 純利益前年比 | 15.5% | 3.9% |
| EPS（希薄化後） | $4.65 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $708.5M | $772.1M | ||
| Q3 25 | $659.9M | $698.9M | ||
| Q2 25 | $603.3M | $720.3M | ||
| Q1 25 | $558.6M | $664.8M | ||
| Q4 24 | $536.6M | $729.4M | ||
| Q3 24 | $533.3M | $684.0M | ||
| Q2 24 | $528.1M | $691.7M | ||
| Q1 24 | $511.0M | $649.9M |
| Q4 25 | $135.1M | $98.4M | ||
| Q3 25 | $111.1M | $46.7M | ||
| Q2 25 | $90.3M | $53.9M | ||
| Q1 25 | $114.6M | $42.2M | ||
| Q4 24 | $117.0M | $94.6M | ||
| Q3 24 | $96.4M | $94.4M | ||
| Q2 24 | $88.4M | $55.4M | ||
| Q1 24 | $102.6M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | 21.6% | 14.5% | ||
| Q3 25 | 21.5% | 11.7% | ||
| Q2 25 | 20.9% | 12.6% | ||
| Q1 25 | 20.3% | 10.9% | ||
| Q4 24 | 23.4% | 16.3% | ||
| Q3 24 | 21.1% | 14.3% | ||
| Q2 24 | 19.9% | 12.4% | ||
| Q1 24 | 20.4% | 6.8% |
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 16.8% | 6.7% | ||
| Q2 25 | 15.0% | 7.5% | ||
| Q1 25 | 20.5% | 6.4% | ||
| Q4 24 | 21.8% | 13.0% | ||
| Q3 24 | 18.1% | 13.8% | ||
| Q2 24 | 16.7% | 8.0% | ||
| Q1 24 | 20.1% | 4.0% |
| Q4 25 | $4.65 | $0.86 | ||
| Q3 25 | $3.86 | $0.40 | ||
| Q2 25 | $3.10 | $0.46 | ||
| Q1 25 | $3.67 | $0.35 | ||
| Q4 24 | $3.67 | $0.77 | ||
| Q3 24 | $3.01 | $0.77 | ||
| Q2 24 | $2.75 | $0.45 | ||
| Q1 24 | $3.20 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $497.0M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $459.1M | $7.3B |
| 総資産 | $2.0B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $497.0M | $919.9M | ||
| Q3 25 | $285.4M | $931.4M | ||
| Q2 25 | $46.3M | $991.8M | ||
| Q1 25 | $441.4M | $1.1B | ||
| Q4 24 | $669.4M | $1.2B | ||
| Q3 24 | $656.9M | $1.2B | ||
| Q2 24 | $510.9M | $2.0B | ||
| Q1 24 | $407.0M | $1.7B |
| Q4 25 | $459.1M | $7.3B | ||
| Q3 25 | $293.6M | $7.4B | ||
| Q2 25 | $172.4M | $7.6B | ||
| Q1 25 | $593.6M | $7.6B | ||
| Q4 24 | $825.5M | $7.7B | ||
| Q3 24 | $881.4M | $7.9B | ||
| Q2 24 | $763.6M | $7.9B | ||
| Q1 24 | $671.5M | $7.8B |
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $192.7M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $188.1M | $161.8M |
| FCFマージンFCF / 売上 | 26.6% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.6% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $681.9M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $192.7M | $182.0M | ||
| Q3 25 | $246.2M | $138.5M | ||
| Q2 25 | $148.5M | $134.3M | ||
| Q1 25 | $125.8M | $128.2M | ||
| Q4 24 | $190.7M | $174.2M | ||
| Q3 24 | $149.1M | $147.9M | ||
| Q2 24 | $116.4M | $158.6M | ||
| Q1 24 | $152.7M | $147.6M |
| Q4 25 | $188.1M | $161.8M | ||
| Q3 25 | $235.5M | $120.0M | ||
| Q2 25 | $142.4M | $115.5M | ||
| Q1 25 | $115.8M | $112.2M | ||
| Q4 24 | $183.0M | $149.8M | ||
| Q3 24 | $138.5M | $125.6M | ||
| Q2 24 | $103.5M | $136.6M | ||
| Q1 24 | $147.2M | $129.7M |
| Q4 25 | 26.6% | 21.0% | ||
| Q3 25 | 35.7% | 17.2% | ||
| Q2 25 | 23.6% | 16.0% | ||
| Q1 25 | 20.7% | 16.9% | ||
| Q4 24 | 34.1% | 20.5% | ||
| Q3 24 | 26.0% | 18.4% | ||
| Q2 24 | 19.6% | 19.7% | ||
| Q1 24 | 28.8% | 20.0% |
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 2.0% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
| Q4 25 | 1.43× | 1.85× | ||
| Q3 25 | 2.22× | 2.97× | ||
| Q2 25 | 1.65× | 2.49× | ||
| Q1 25 | 1.10× | 3.03× | ||
| Q4 24 | 1.63× | 1.84× | ||
| Q3 24 | 1.55× | 1.57× | ||
| Q2 24 | 1.32× | 2.87× | ||
| Q1 24 | 1.49× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
